-
1.发明授权USE OF OLIGONUCLEOTIDES HAVING A CONSERVED G 4 CORE SEQUENCE FOR THE PREPARATION OF A MEDICAMENT 失效具有保持G4 KEY序列的寡核苷酸用于生产药物的应用
公开(公告)号：EP0672193B1
公开(公告)日：2002-08-14
申请号：EP93922788.0
申请日：1993-09-29
发明人： HANECAK, Ronnie, C. , ANDERSON, Kevin, P. , BENNETT, C., Frank , CHIANG, Ming-Yi , BROWN-DRIVER, Vickie, L. , ECKER, David, J. , VICKERS, Timothy, A. , WYATT, Jacqueline, R. , IMBACH, Jean, Louis Impasse des Lucques
CPC分类号： A61K31/70 , A61K38/00 , C07H21/00 , C12N15/1133 , C12N15/1137 , C12N15/115 , C12N15/117 , C12N2310/151 , C12N2310/18 , C12N2310/315 , C12N2310/321 , C12N2310/341 , C12N2310/346 , C12Q1/701 , C12Y207/07049 , C12Y301/01004 , C12N2310/3521
摘要： Modified oligonucleotides having a conserved G4 sequence and a sufficient number of flanking nucleotides to significantly inhibit the activity of a virus such as HSV-1 or phospholipase A2 or to modulate the telomere length of a chromosome are provided. G4 quartet oligonucleotide structures are also provided. Methods of prophylaxis, diagnostics and therapeutics for viral-associated diseases and diseases associated with elevated levels of phospholipase A2 are also provided. Methods of modulating telomere length of a chromosome are also provided; modulation of telomere length is believed to play a role in the aging process of a cell and in control of malignant cell growth.
-
公开(公告)号：EP0672193A1
公开(公告)日：1995-09-20
申请号：EP93922788.0
申请日：1993-09-29
发明人： HANECAK, Ronnie, C. , ANDERSON, Kevin, P. , BENNETT, C., Frank , CHIANG, Ming-Yi , BROWN-DRIVER, Vickie, L. , ECKER, David, J. , VICKERS, Timothy, A. , WYATT, Jacqueline, R. , IMBACH, Jean, Louis Impasse des Lucques
CPC分类号： A61K31/70 , A61K38/00 , C07H21/00 , C12N15/1133 , C12N15/1137 , C12N15/115 , C12N15/117 , C12N2310/151 , C12N2310/18 , C12N2310/315 , C12N2310/321 , C12N2310/341 , C12N2310/346 , C12Q1/701 , C12Y207/07049 , C12Y301/01004 , C12N2310/3521
摘要： Modified oligonucleotides having a conserved G4 sequence and a sufficient number of flanking nucleotides to significantly inhibit the activity of a virus such as HSV-1 or phospholipase A2 or to modulate the telomere length of a chromosome are provided. G4 quartet oligonucleotide structures are also provided. Methods of prophylaxis, diagnostics and therapeutics for viral-associated diseases and diseases associated with elevated levels of phospholipase A2 are also provided. Methods of modulating telomere length of a chromosome are also provided; modulation of telomere length is believed to play a role in the aging process of a cell and in control of malignant cell growth.
-
搜索结果
2 条记录 (耗时 0.009 秒)
